Juno Therapeutics Could Now Return 18.6%, Vetr Crowd Says

Shares of Juno Therapeutics Inc JUNO have gained more than 4.4 percent since the year started, outperforming major stock indexes. Moreover, in the past month, the stock spiked up more than 19.3 percent. The Vetr crowd seems to believe the rally will continue, as evidenced by its average price target of $54.66, which implies an upside potential of roughly 18.6 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Juno Therapeutics on Thursday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.

It should be noted that only 57 percent of the crowd’s ratings are bullish, as only recently did the Vetr community become positive on the stock.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.